Introduction
The last ten biopharma companies that have IPO’d on the STAR Market (Shanghai Stock Exchange Science and Technology Innovation Board) are focused on oncology, synthetic biology, genomics, HIV & pain management, vaccines, antibodies, and other biologics and small molecules. Figure 1 shows the global pharmaceutical market share of these categories as of 2020. Biologics and small molecules combined represent the majority of the biopharmaceutical market.
Figure 1: 2020 global market share vs. category.
Four of the last ten companies to IPO are large generalist biopharmaceutical companies that cover the full range of therapeutics and disease indications. One of the companies is focused on the major antibody market. The remaining companies were diverse focussing on different aspects of the aforementioned categories.
Biopharmaceutical IPOs
Sinopep-Allsino Biopharmaceutical Co., Ltd.
Sinopep is a market-oriented, innovation-driven biopharmaceutical company. The R&D, manufacturing and sales is of both peptide and small molecule pharmaceuticals. Over more than 11 years, the company has successfully developed five technology platforms; 1) large scale solid-solution phase hybrid production technology, 2) chiral-drug design and selection technology, 3) continuous-flow microchannel green-chemistry technology, 4) drug delivery technology, 5) new peptide drug design technology.
Sinopep has an extensive IP portfolio with 53 patents for various inventions, which are widely used in the research, development and production for the company's products. The company produces a wide range of products for indications such as diabetes, cardiovascular, oncology, antiviral, and assisted fertility.
Sinopep’s key products are liraglutide, semaglutide, thymalfasin, eptifibatide, bivalirudin, octreotide acetate, lanreotide acetate, cetrorelix, fulvestrant, oseltamivir.
Youcare Pharmaceutical Group Co., Ltd.
Headquartered in Beijing, Youcare Pharmaceutical Group was founded in 2001. Youcare has established a pharmaceutical research institute in Beijing, and different manufacturing bases in Beijing, Guangzhou, Anhui, and Henan.
The company follows clinical needs as guidance. Youcare has consecutively established the National and Local Joint Engineering Laboratory for Cephalosporin Crystal Form Research, Beijing Engineering Research Center for Cardio-cerebral Vascular Medicine and the Technological Development Platform for Micro-pellet Sustained-Release and Controlled-Release Preparations, and established a Youcare Group Academic Expert Workstation, and Postdoctoral Research Station.
The company currently has over 200 drug products, covering multiple therapeutic fields including cardio-cerebral vascular drugs, gastrointestinal drugs,anti infective agents, endocrine drugs and antineoplastic drugs.
Shan Dong Kexing Bioproducts Co., Ltd
Kexing Biopharmaceutical Co., Ltd., engages in the research and development, production, and sale of recombinant protein therapeutics and microbiota agents. The company was founded in 1997 and is based in Jinan, China. Its pharmaceutical research focuses on the therapeutic fields of antiviral, hematology, oncology, and immunology, as well as degenerative diseases. The company’s products include recombinant human interferon a1b, recombinant human erythropoietin, and recombinant human granulocyte colony-stimulating factor injections, as well as combined clostridium butyricum and bifidobacterium capsules.
Chengdu Easton Biopharmaceuticals Co.,Ltd.
Founded in 2009 , Easton Biopharmaceuticals is a high-tech enterprise integrating R&D, production and sales of chemical raw materials, high-end chemical medicines and biopharmaceuticals with approximately 1,000 employees.
Taking on the “Healthy China Initiative”, the company is devoted to drug research and development, focused on major diseases such as anesthesiology & pain management, cardiovascular, oncology, children's medicines, and diabetes. By the end of April 2021, it had industrialized 26 high-end chemical drugs and 17 ch...
(All Rights Reserved)